Review



rabbit anti mouse cxcl13 polyclonal antibody  (Biorbyt)


Bioz Verified Symbol Biorbyt is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    Biorbyt rabbit anti mouse cxcl13 polyclonal antibody
    Primer sequences.
    Rabbit Anti Mouse Cxcl13 Polyclonal Antibody, supplied by Biorbyt, used in various techniques. Bioz Stars score: 91/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti mouse cxcl13 polyclonal antibody/product/Biorbyt
    Average 91 stars, based on 4 article reviews
    rabbit anti mouse cxcl13 polyclonal antibody - by Bioz Stars, 2026-03
    91/100 stars

    Images

    1) Product Images from "Signaling via the CXCR5/ERK pathway is mediated by CXCL13 in mice with breast cancer"

    Article Title: Signaling via the CXCR5/ERK pathway is mediated by CXCL13 in mice with breast cancer

    Journal: Oncology Letters

    doi: 10.3892/ol.2018.8510

    Primer sequences.
    Figure Legend Snippet: Primer sequences.

    Techniques Used:

    Effect of CXCL13 on tumor volume in Control, Model and Inhibitor group mice. Female BALB/c mice were randomly divided into three groups: Control; Model (inoculated with 1×105 4T1 cells); Inhibitor (inoculated with 4 mg/kg goat anti-mouse CXCL13 polyclonal antibody at day −2, −1 and 0, then injected with 1×105 4T1 cells). The tumor volume of the three groups was calculated on days 6, 12 and 18. *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C motif chemokine ligand 13.
    Figure Legend Snippet: Effect of CXCL13 on tumor volume in Control, Model and Inhibitor group mice. Female BALB/c mice were randomly divided into three groups: Control; Model (inoculated with 1×105 4T1 cells); Inhibitor (inoculated with 4 mg/kg goat anti-mouse CXCL13 polyclonal antibody at day −2, −1 and 0, then injected with 1×105 4T1 cells). The tumor volume of the three groups was calculated on days 6, 12 and 18. *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C motif chemokine ligand 13.

    Techniques Used: Control, Injection

    Effects of CXCL13 on tumor morphology from H&E staining in the Model and Inhibitor groups. After 9 weeks, all mice were sacrificed and the tumor tissues were sectioned and H&E stained for morphology observation. Images are of ×100 magnification. CXCL13, C-X-C motif chemokine ligand 13; H&E, hematoxylin and eosin staining.
    Figure Legend Snippet: Effects of CXCL13 on tumor morphology from H&E staining in the Model and Inhibitor groups. After 9 weeks, all mice were sacrificed and the tumor tissues were sectioned and H&E stained for morphology observation. Images are of ×100 magnification. CXCL13, C-X-C motif chemokine ligand 13; H&E, hematoxylin and eosin staining.

    Techniques Used: Staining

    Effects of CXCL13 on the mRNA expression of 3 key genes of the CXCR5/ERK pathway (CXCL13, CXCR5 and ERK) in the Control, Model and Inhibitor groups. The relative mRNA expression was normalized to β-actin. *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C motif chemokine ligand 13; CXCR5, C-X-C motif chemokine receptor 5; ERK, extracellular-regulated protein kinases; p-ERK, phosphorylated-ERK.
    Figure Legend Snippet: Effects of CXCL13 on the mRNA expression of 3 key genes of the CXCR5/ERK pathway (CXCL13, CXCR5 and ERK) in the Control, Model and Inhibitor groups. The relative mRNA expression was normalized to β-actin. *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C motif chemokine ligand 13; CXCR5, C-X-C motif chemokine receptor 5; ERK, extracellular-regulated protein kinases; p-ERK, phosphorylated-ERK.

    Techniques Used: Expressing, Control

    Effects of CXCL13 on the expression levels of three key proteins of the CXCR5/ERK pathway (CXCL13, CXCR5 and p-ERK) was analyzed in the Control, Model and Inhibitor groups. (A) Western blot analysis demonstrating that CXCL13, CXCR5 and p-ERK protein levels increased, with an increased p-ERK/ERK ratio, in the Model and Inhibitor groups compared with those in the Control group. The protein levels of CXCL13, CXCR5 and p-ERK decreased and the ratio of p-ERK/ERK decreased with CXCL13 inhibition. (B) Quantification of the western blot allowed for statistical analysis of the relative levels of proteins (normalized to β-actin). *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C Motif Chemokine Ligand 13; CXCR5, C-X-C motif chemokine receptor 5; ERK, extracellular-regulated protein kinases; p-ERK, phosphorylated-ERK.
    Figure Legend Snippet: Effects of CXCL13 on the expression levels of three key proteins of the CXCR5/ERK pathway (CXCL13, CXCR5 and p-ERK) was analyzed in the Control, Model and Inhibitor groups. (A) Western blot analysis demonstrating that CXCL13, CXCR5 and p-ERK protein levels increased, with an increased p-ERK/ERK ratio, in the Model and Inhibitor groups compared with those in the Control group. The protein levels of CXCL13, CXCR5 and p-ERK decreased and the ratio of p-ERK/ERK decreased with CXCL13 inhibition. (B) Quantification of the western blot allowed for statistical analysis of the relative levels of proteins (normalized to β-actin). *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C Motif Chemokine Ligand 13; CXCR5, C-X-C motif chemokine receptor 5; ERK, extracellular-regulated protein kinases; p-ERK, phosphorylated-ERK.

    Techniques Used: Expressing, Control, Western Blot, Inhibition

    Effects of CXCL13 on the concentrations of three cytokines (IL-1β, TNF and TGF-β1) were analyzed by ELISA in the Control, Model and Inhibitor groups. *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C motif chemokine ligand 13; IL-1β, interleukin-1β; TNF, tumor necrosis factor; TGF-β1, transforming growth factor β1.
    Figure Legend Snippet: Effects of CXCL13 on the concentrations of three cytokines (IL-1β, TNF and TGF-β1) were analyzed by ELISA in the Control, Model and Inhibitor groups. *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C motif chemokine ligand 13; IL-1β, interleukin-1β; TNF, tumor necrosis factor; TGF-β1, transforming growth factor β1.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Control



    Similar Products

    rabbit polyclonal anti mouse cxcl13  (Bioss)
    86
    Bioss rabbit polyclonal anti mouse cxcl13
    (A) Foxp3+ (green), B cells (blue), and CD4+ T cells (red) in BALB/c lungs at least 30 days after transplantation into immunosuppressed B6 Foxp3-IRES GFP recipient (n = 3). Scale bar: 10 μm. CXCR5+ B cells from secondary host (recipient) in BALB/c lungs, initially transplanted into immunosuppressed (B) WT or (C) Foxp3-DTR B6 (CD45.2+) recipient and, at least 30 days later, retransplanted into DT-treated B6 CD45.1+ hosts. Plots are gated on live CD45.2–CD45.1+ cells. (D) CD45.1+CXCR5+ B cells in (circles) control and (inverted triangles) Foxp3+ T cell–depleted lungs 7 days after retransplantation (n = 4 each). <t>CXCL13</t> (brown) in (E) control and (F) Foxp3+ T cell–depleted grafts 7 days after retransplantation. Scale bars: 100 μm. CD4+ T cells (green) and B cells (blue) in BALB/c lungs, initially transplanted into immunosuppressed B6 Foxp3-DTR recipients and, at least 30 days later, retransplanted into B6 hosts, treated with (G) DT/control-Ig (arrows: CD4+ T–B cell interactions) or (H) DT/anti-CXCL13 (n = 2 each) (red, quantum dots). Scale bars: 20 μm. (I) Contact duration between CD4+ T and B cells, (J) CD4+ T, and (K) B cell mean square displacements and (L) CD4+ T and (M) B cell velocities within retransplanted Foxp3+ T cell–depleted BALB/c lungs with and without CXCL13 inhibition. (N) Gross, (O) histological appearance (H&E), staining for (P) MT (blue), (Q) CCSP (red), and AcT (green) in BALB/c lungs, transplanted into immunosuppressed B6 Foxp3-DTR mice and, at least 30 days later, retransplanted into DT- and anti-CXCL13–treated B6 hosts. Scale bars: 100 μm. (R) Donor-specific IgM titers after retransplantation of BALB/c lungs into DT-treated control (blue) or DT/anti-CXCL13 antibody–treated (red) B6 recipients after initial engraftment into immunosuppressed B6 Foxp3-DTR mice (n = 4 mice per group). Data are expressed as mean ± SEM. Mann-Whitney U test was used to compare the means.
    Rabbit Polyclonal Anti Mouse Cxcl13, supplied by Bioss, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal anti mouse cxcl13/product/Bioss
    Average 86 stars, based on 1 article reviews
    rabbit polyclonal anti mouse cxcl13 - by Bioz Stars, 2026-03
    86/100 stars
    		  Buy from Supplier
    rabbit anti mouse cxcl13 polyclonal antibody  (Biorbyt)
    91
    Biorbyt rabbit anti mouse cxcl13 polyclonal antibody
    Primer sequences.
    Rabbit Anti Mouse Cxcl13 Polyclonal Antibody, supplied by Biorbyt, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti mouse cxcl13 polyclonal antibody/product/Biorbyt
    Average 91 stars, based on 1 article reviews
    rabbit anti mouse cxcl13 polyclonal antibody - by Bioz Stars, 2026-03
    91/100 stars
    		  Buy from Supplier
    polyclonal rabbit anti-mouse cxcl13 antibody  (Thermo Fisher)
    90
    Thermo Fisher polyclonal rabbit anti-mouse cxcl13 antibody
    Primer sequences.
    Polyclonal Rabbit Anti Mouse Cxcl13 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal rabbit anti-mouse cxcl13 antibody/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    polyclonal rabbit anti-mouse cxcl13 antibody - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Foxp3+ (green), B cells (blue), and CD4+ T cells (red) in BALB/c lungs at least 30 days after transplantation into immunosuppressed B6 Foxp3-IRES GFP recipient (n = 3). Scale bar: 10 μm. CXCR5+ B cells from secondary host (recipient) in BALB/c lungs, initially transplanted into immunosuppressed (B) WT or (C) Foxp3-DTR B6 (CD45.2+) recipient and, at least 30 days later, retransplanted into DT-treated B6 CD45.1+ hosts. Plots are gated on live CD45.2–CD45.1+ cells. (D) CD45.1+CXCR5+ B cells in (circles) control and (inverted triangles) Foxp3+ T cell–depleted lungs 7 days after retransplantation (n = 4 each). CXCL13 (brown) in (E) control and (F) Foxp3+ T cell–depleted grafts 7 days after retransplantation. Scale bars: 100 μm. CD4+ T cells (green) and B cells (blue) in BALB/c lungs, initially transplanted into immunosuppressed B6 Foxp3-DTR recipients and, at least 30 days later, retransplanted into B6 hosts, treated with (G) DT/control-Ig (arrows: CD4+ T–B cell interactions) or (H) DT/anti-CXCL13 (n = 2 each) (red, quantum dots). Scale bars: 20 μm. (I) Contact duration between CD4+ T and B cells, (J) CD4+ T, and (K) B cell mean square displacements and (L) CD4+ T and (M) B cell velocities within retransplanted Foxp3+ T cell–depleted BALB/c lungs with and without CXCL13 inhibition. (N) Gross, (O) histological appearance (H&E), staining for (P) MT (blue), (Q) CCSP (red), and AcT (green) in BALB/c lungs, transplanted into immunosuppressed B6 Foxp3-DTR mice and, at least 30 days later, retransplanted into DT- and anti-CXCL13–treated B6 hosts. Scale bars: 100 μm. (R) Donor-specific IgM titers after retransplantation of BALB/c lungs into DT-treated control (blue) or DT/anti-CXCL13 antibody–treated (red) B6 recipients after initial engraftment into immunosuppressed B6 Foxp3-DTR mice (n = 4 mice per group). Data are expressed as mean ± SEM. Mann-Whitney U test was used to compare the means.

    Journal: The Journal of Clinical Investigation

    Article Title: Bronchus-associated lymphoid tissue–resident Foxp3 + T lymphocytes prevent antibody-mediated lung rejection

    doi: 10.1172/JCI122083

    Figure Lengend Snippet: (A) Foxp3+ (green), B cells (blue), and CD4+ T cells (red) in BALB/c lungs at least 30 days after transplantation into immunosuppressed B6 Foxp3-IRES GFP recipient (n = 3). Scale bar: 10 μm. CXCR5+ B cells from secondary host (recipient) in BALB/c lungs, initially transplanted into immunosuppressed (B) WT or (C) Foxp3-DTR B6 (CD45.2+) recipient and, at least 30 days later, retransplanted into DT-treated B6 CD45.1+ hosts. Plots are gated on live CD45.2–CD45.1+ cells. (D) CD45.1+CXCR5+ B cells in (circles) control and (inverted triangles) Foxp3+ T cell–depleted lungs 7 days after retransplantation (n = 4 each). CXCL13 (brown) in (E) control and (F) Foxp3+ T cell–depleted grafts 7 days after retransplantation. Scale bars: 100 μm. CD4+ T cells (green) and B cells (blue) in BALB/c lungs, initially transplanted into immunosuppressed B6 Foxp3-DTR recipients and, at least 30 days later, retransplanted into B6 hosts, treated with (G) DT/control-Ig (arrows: CD4+ T–B cell interactions) or (H) DT/anti-CXCL13 (n = 2 each) (red, quantum dots). Scale bars: 20 μm. (I) Contact duration between CD4+ T and B cells, (J) CD4+ T, and (K) B cell mean square displacements and (L) CD4+ T and (M) B cell velocities within retransplanted Foxp3+ T cell–depleted BALB/c lungs with and without CXCL13 inhibition. (N) Gross, (O) histological appearance (H&E), staining for (P) MT (blue), (Q) CCSP (red), and AcT (green) in BALB/c lungs, transplanted into immunosuppressed B6 Foxp3-DTR mice and, at least 30 days later, retransplanted into DT- and anti-CXCL13–treated B6 hosts. Scale bars: 100 μm. (R) Donor-specific IgM titers after retransplantation of BALB/c lungs into DT-treated control (blue) or DT/anti-CXCL13 antibody–treated (red) B6 recipients after initial engraftment into immunosuppressed B6 Foxp3-DTR mice (n = 4 mice per group). Data are expressed as mean ± SEM. Mann-Whitney U test was used to compare the means.

    Article Snippet: Primary antibodies used were rabbit monoclonal anti-human Foxp3 (clone SP97, 1:400, Novus), rabbit polyclonal anti-mouse CXCL13 (1:100, Bioss), and rat monoclonal anti-mouse PNAd (clone MECA-79, 1:100, BD Biosciences).

    Techniques: Transplantation Assay, Inhibition, Staining, MANN-WHITNEY

    Primer sequences.

    Journal: Oncology Letters

    Article Title: Signaling via the CXCR5/ERK pathway is mediated by CXCL13 in mice with breast cancer

    doi: 10.3892/ol.2018.8510

    Figure Lengend Snippet: Primer sequences.

    Article Snippet: The membrane was blocked with 5% skimmed milk for 1 h at room temperature, prior to an overnight incubation at 4°C with rabbit anti-mouse CXCL13 polyclonal antibody (dilution, 1:500; cat no. orb101825; Biorbyt Ltd., Cambridge, UK), rabbit anti-mouse CXCR5 monoclonal antibody (dilution, 1:500; cat no. orb5925; Biorbyt Ltd.), rabbit anti-p-ERK polyclonal antibody (dilution, 1:500; cat no. orb1733; Biorbyt Ltd.), rabbit anti-ERK polyclonal antibody (dilution, 1:500; cat no. orb224458; Biorbyt Ltd.) and rabbit anti-β-actin polyclonal antibody (dilution, 1:500; cat no. orb 129534; Biorbyt Ltd.).

    Techniques:

    Effect of CXCL13 on tumor volume in Control, Model and Inhibitor group mice. Female BALB/c mice were randomly divided into three groups: Control; Model (inoculated with 1×105 4T1 cells); Inhibitor (inoculated with 4 mg/kg goat anti-mouse CXCL13 polyclonal antibody at day −2, −1 and 0, then injected with 1×105 4T1 cells). The tumor volume of the three groups was calculated on days 6, 12 and 18. *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C motif chemokine ligand 13.

    Journal: Oncology Letters

    Article Title: Signaling via the CXCR5/ERK pathway is mediated by CXCL13 in mice with breast cancer

    doi: 10.3892/ol.2018.8510

    Figure Lengend Snippet: Effect of CXCL13 on tumor volume in Control, Model and Inhibitor group mice. Female BALB/c mice were randomly divided into three groups: Control; Model (inoculated with 1×105 4T1 cells); Inhibitor (inoculated with 4 mg/kg goat anti-mouse CXCL13 polyclonal antibody at day −2, −1 and 0, then injected with 1×105 4T1 cells). The tumor volume of the three groups was calculated on days 6, 12 and 18. *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C motif chemokine ligand 13.

    Article Snippet: The membrane was blocked with 5% skimmed milk for 1 h at room temperature, prior to an overnight incubation at 4°C with rabbit anti-mouse CXCL13 polyclonal antibody (dilution, 1:500; cat no. orb101825; Biorbyt Ltd., Cambridge, UK), rabbit anti-mouse CXCR5 monoclonal antibody (dilution, 1:500; cat no. orb5925; Biorbyt Ltd.), rabbit anti-p-ERK polyclonal antibody (dilution, 1:500; cat no. orb1733; Biorbyt Ltd.), rabbit anti-ERK polyclonal antibody (dilution, 1:500; cat no. orb224458; Biorbyt Ltd.) and rabbit anti-β-actin polyclonal antibody (dilution, 1:500; cat no. orb 129534; Biorbyt Ltd.).

    Techniques: Control, Injection

    Effects of CXCL13 on tumor morphology from H&E staining in the Model and Inhibitor groups. After 9 weeks, all mice were sacrificed and the tumor tissues were sectioned and H&E stained for morphology observation. Images are of ×100 magnification. CXCL13, C-X-C motif chemokine ligand 13; H&E, hematoxylin and eosin staining.

    Journal: Oncology Letters

    Article Title: Signaling via the CXCR5/ERK pathway is mediated by CXCL13 in mice with breast cancer

    doi: 10.3892/ol.2018.8510

    Figure Lengend Snippet: Effects of CXCL13 on tumor morphology from H&E staining in the Model and Inhibitor groups. After 9 weeks, all mice were sacrificed and the tumor tissues were sectioned and H&E stained for morphology observation. Images are of ×100 magnification. CXCL13, C-X-C motif chemokine ligand 13; H&E, hematoxylin and eosin staining.

    Article Snippet: The membrane was blocked with 5% skimmed milk for 1 h at room temperature, prior to an overnight incubation at 4°C with rabbit anti-mouse CXCL13 polyclonal antibody (dilution, 1:500; cat no. orb101825; Biorbyt Ltd., Cambridge, UK), rabbit anti-mouse CXCR5 monoclonal antibody (dilution, 1:500; cat no. orb5925; Biorbyt Ltd.), rabbit anti-p-ERK polyclonal antibody (dilution, 1:500; cat no. orb1733; Biorbyt Ltd.), rabbit anti-ERK polyclonal antibody (dilution, 1:500; cat no. orb224458; Biorbyt Ltd.) and rabbit anti-β-actin polyclonal antibody (dilution, 1:500; cat no. orb 129534; Biorbyt Ltd.).

    Techniques: Staining

    Effects of CXCL13 on the mRNA expression of 3 key genes of the CXCR5/ERK pathway (CXCL13, CXCR5 and ERK) in the Control, Model and Inhibitor groups. The relative mRNA expression was normalized to β-actin. *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C motif chemokine ligand 13; CXCR5, C-X-C motif chemokine receptor 5; ERK, extracellular-regulated protein kinases; p-ERK, phosphorylated-ERK.

    Journal: Oncology Letters

    Article Title: Signaling via the CXCR5/ERK pathway is mediated by CXCL13 in mice with breast cancer

    doi: 10.3892/ol.2018.8510

    Figure Lengend Snippet: Effects of CXCL13 on the mRNA expression of 3 key genes of the CXCR5/ERK pathway (CXCL13, CXCR5 and ERK) in the Control, Model and Inhibitor groups. The relative mRNA expression was normalized to β-actin. *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C motif chemokine ligand 13; CXCR5, C-X-C motif chemokine receptor 5; ERK, extracellular-regulated protein kinases; p-ERK, phosphorylated-ERK.

    Article Snippet: The membrane was blocked with 5% skimmed milk for 1 h at room temperature, prior to an overnight incubation at 4°C with rabbit anti-mouse CXCL13 polyclonal antibody (dilution, 1:500; cat no. orb101825; Biorbyt Ltd., Cambridge, UK), rabbit anti-mouse CXCR5 monoclonal antibody (dilution, 1:500; cat no. orb5925; Biorbyt Ltd.), rabbit anti-p-ERK polyclonal antibody (dilution, 1:500; cat no. orb1733; Biorbyt Ltd.), rabbit anti-ERK polyclonal antibody (dilution, 1:500; cat no. orb224458; Biorbyt Ltd.) and rabbit anti-β-actin polyclonal antibody (dilution, 1:500; cat no. orb 129534; Biorbyt Ltd.).

    Techniques: Expressing, Control

    Effects of CXCL13 on the expression levels of three key proteins of the CXCR5/ERK pathway (CXCL13, CXCR5 and p-ERK) was analyzed in the Control, Model and Inhibitor groups. (A) Western blot analysis demonstrating that CXCL13, CXCR5 and p-ERK protein levels increased, with an increased p-ERK/ERK ratio, in the Model and Inhibitor groups compared with those in the Control group. The protein levels of CXCL13, CXCR5 and p-ERK decreased and the ratio of p-ERK/ERK decreased with CXCL13 inhibition. (B) Quantification of the western blot allowed for statistical analysis of the relative levels of proteins (normalized to β-actin). *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C Motif Chemokine Ligand 13; CXCR5, C-X-C motif chemokine receptor 5; ERK, extracellular-regulated protein kinases; p-ERK, phosphorylated-ERK.

    Journal: Oncology Letters

    Article Title: Signaling via the CXCR5/ERK pathway is mediated by CXCL13 in mice with breast cancer

    doi: 10.3892/ol.2018.8510

    Figure Lengend Snippet: Effects of CXCL13 on the expression levels of three key proteins of the CXCR5/ERK pathway (CXCL13, CXCR5 and p-ERK) was analyzed in the Control, Model and Inhibitor groups. (A) Western blot analysis demonstrating that CXCL13, CXCR5 and p-ERK protein levels increased, with an increased p-ERK/ERK ratio, in the Model and Inhibitor groups compared with those in the Control group. The protein levels of CXCL13, CXCR5 and p-ERK decreased and the ratio of p-ERK/ERK decreased with CXCL13 inhibition. (B) Quantification of the western blot allowed for statistical analysis of the relative levels of proteins (normalized to β-actin). *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C Motif Chemokine Ligand 13; CXCR5, C-X-C motif chemokine receptor 5; ERK, extracellular-regulated protein kinases; p-ERK, phosphorylated-ERK.

    Article Snippet: The membrane was blocked with 5% skimmed milk for 1 h at room temperature, prior to an overnight incubation at 4°C with rabbit anti-mouse CXCL13 polyclonal antibody (dilution, 1:500; cat no. orb101825; Biorbyt Ltd., Cambridge, UK), rabbit anti-mouse CXCR5 monoclonal antibody (dilution, 1:500; cat no. orb5925; Biorbyt Ltd.), rabbit anti-p-ERK polyclonal antibody (dilution, 1:500; cat no. orb1733; Biorbyt Ltd.), rabbit anti-ERK polyclonal antibody (dilution, 1:500; cat no. orb224458; Biorbyt Ltd.) and rabbit anti-β-actin polyclonal antibody (dilution, 1:500; cat no. orb 129534; Biorbyt Ltd.).

    Techniques: Expressing, Control, Western Blot, Inhibition

    Effects of CXCL13 on the concentrations of three cytokines (IL-1β, TNF and TGF-β1) were analyzed by ELISA in the Control, Model and Inhibitor groups. *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C motif chemokine ligand 13; IL-1β, interleukin-1β; TNF, tumor necrosis factor; TGF-β1, transforming growth factor β1.

    Journal: Oncology Letters

    Article Title: Signaling via the CXCR5/ERK pathway is mediated by CXCL13 in mice with breast cancer

    doi: 10.3892/ol.2018.8510

    Figure Lengend Snippet: Effects of CXCL13 on the concentrations of three cytokines (IL-1β, TNF and TGF-β1) were analyzed by ELISA in the Control, Model and Inhibitor groups. *P<0.05 vs. Control group; #P<0.05 vs. Model group. CXCL13, C-X-C motif chemokine ligand 13; IL-1β, interleukin-1β; TNF, tumor necrosis factor; TGF-β1, transforming growth factor β1.

    Article Snippet: The membrane was blocked with 5% skimmed milk for 1 h at room temperature, prior to an overnight incubation at 4°C with rabbit anti-mouse CXCL13 polyclonal antibody (dilution, 1:500; cat no. orb101825; Biorbyt Ltd., Cambridge, UK), rabbit anti-mouse CXCR5 monoclonal antibody (dilution, 1:500; cat no. orb5925; Biorbyt Ltd.), rabbit anti-p-ERK polyclonal antibody (dilution, 1:500; cat no. orb1733; Biorbyt Ltd.), rabbit anti-ERK polyclonal antibody (dilution, 1:500; cat no. orb224458; Biorbyt Ltd.) and rabbit anti-β-actin polyclonal antibody (dilution, 1:500; cat no. orb 129534; Biorbyt Ltd.).

    Techniques: Enzyme-linked Immunosorbent Assay, Control